Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Paul Blachman

Neurology South Weymouth, MA Medical Doctor

NPI 1669462578 CMS profile 120650

851 Main St, Ste 11, South Weymouth, MA 02190

Open in the dashboard

General payments

$5,571

17 records reported · program years 2019–2021

Research payments

$490

Paid to them · 1 record reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Paul Blachman of South Weymouth, MA is reported in the CMS Open Payments database as having received $5,571 across 17 general payments and $490 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,708 3
2020 General $2,713 13
2020 Research $490 1
2019 General $150 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Blachman
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Paul Blachman were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Paul Blachman Neurology median Middle half National median
2019 $150 $474 $118–$2,177 $163
2020 $2,713 $367 $82–$2,309 $114
2021 $2,708 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Allergan Inc. $2,694 12 payments
  2. Eisai Inc. $1,568 1 payment
  3. Banner Life Sciences, LLC $900 1 payment
  4. Genzyme Corporation $240 1 payment
  5. Biogen, Inc. $150 1 payment
  6. Novartis Pharmaceuticals Corporation $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,940 3 payments
  2. Consulting Fee $1,718 2 payments
  3. Honoraria $900 1 payment
  4. Travel and Lodging $608 5 payments
  5. Food and Beverage $405 6 payments
Products named General payments · program years 2019–2021
  1. UBRELVY $2,694 12 payments
  2. BAFIERTAM $900 1 payment
  3. AUBAGIO $240 1 payment
  4. TYSABRI $150 1 payment
  5. AIMOVIG $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. Avanir Pharmaceuticals, Inc. $490 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,987

Median for Neurology: 833

Drug cost

$465,982

Median for Neurology: $202,670

Branded share of claims

27.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 106 $175,771
Emgality Pen Galcanezumab-Gnlm Brand 100 $71,660
Nuplazid Pimavanserin Tartrate Brand 12 $50,483
Qulipta Atogepant Brand 21 $26,043
Ubrelvy Ubrogepant Brand 16 $20,860
Memantine Hcl Generic 254 $13,406
Emgality Syringe Galcanezumab-Gnlm Brand 11 $8,915
Rivastigmine Generic 28 $8,176
Carbamazepine Er Carbamazepine Brand 71 $7,832
Lamotrigine Odt Lamotrigine Brand 25 $7,690

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$103,539

Medicare's payments for the services billed

Medicare patients

709

Average age 75

Services billed

1,042

396 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 28%
Depression 26%
Chronic kidney disease 24%
Diabetes 23%
Atrial fibrillation 23%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record